Tidal Investments LLC Grows Position in Insulet Co. (NASDAQ:PODD)

Tidal Investments LLC lifted its holdings in Insulet Co. (NASDAQ:PODD) by 5.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,365 shares of the medical instruments supplier’s stock after buying an additional 466 shares during the period. Tidal Investments LLC’s holdings in Insulet were worth $2,180,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently bought and sold shares of PODD. Blue Trust Inc. lifted its stake in Insulet by 84.1% in the 3rd quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock worth $30,000 after purchasing an additional 58 shares in the last quarter. International Assets Investment Management LLC purchased a new position in Insulet during the second quarter worth approximately $32,000. Venturi Wealth Management LLC boosted its stake in Insulet by 633.3% during the third quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier’s stock worth $36,000 after buying an additional 133 shares during the last quarter. UMB Bank n.a. grew its holdings in Insulet by 81.0% in the 2nd quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier’s stock valued at $37,000 after buying an additional 81 shares in the last quarter. Finally, 1620 Investment Advisors Inc. acquired a new stake in shares of Insulet in the 2nd quarter worth $52,000.

Insulet Trading Down 1.4 %

Shares of PODD stock opened at $265.50 on Tuesday. Insulet Co. has a fifty-two week low of $160.19 and a fifty-two week high of $279.77. The company has a 50 day moving average price of $252.13 and a 200 day moving average price of $221.28. The stock has a market capitalization of $18.62 billion, a P/E ratio of 45.46, a price-to-earnings-growth ratio of 4.12 and a beta of 1.21. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on PODD shares. Sanford C. Bernstein began coverage on shares of Insulet in a report on Wednesday, November 6th. They issued an “outperform” rating and a $300.00 price objective for the company. BTIG Research raised their price target on shares of Insulet from $260.00 to $270.00 and gave the stock a “buy” rating in a report on Friday, November 8th. Barclays upped their price objective on Insulet from $220.00 to $234.00 and gave the company an “equal weight” rating in a report on Monday, November 11th. Raymond James raised their target price on Insulet from $213.00 to $260.00 and gave the stock an “outperform” rating in a research note on Monday, October 14th. Finally, Piper Sandler increased their price target on Insulet from $230.00 to $285.00 and gave the stock an “overweight” rating in a report on Tuesday, September 17th. Three investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $267.44.

Insiders Place Their Bets

In related news, CAO Lauren Budden sold 915 shares of Insulet stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $275.62, for a total value of $252,192.30. Following the completion of the transaction, the chief accounting officer now directly owns 5,733 shares in the company, valued at approximately $1,580,129.46. This trade represents a 13.76 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.47% of the company’s stock.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.